GlassScriptPhysician profile
Nader Kassis Akl
NPI 1407086325
$4,547.16
in general payments reported to CMS, 2019-2025
40 companies · $987 in 2025
The $987 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $157 · 2021: $102 · 2022: $181 · 2023: $696 · 2024: $1,384 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.62 |
| Education | $185.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $418.79 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $400.62 | 2022-2025 | Tarpeyo |
| Amgen INC. | $378.18 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $280.97 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $266.87 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Akebia Therapeutics INC | $238.99 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.59 | 2023-2025 | |
| Ardelyx, INC. | $208.54 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Enterprises LLC | $183.34 | 2019 | |
| Opko Pharmaceuticals, LLC | $165.22 | 2023-2024 | Rayaldee |
| Chiesi USA, INC. | $154.24 | 2024 | Elfabrio |
| Novo Nordisk INC | $150.21 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $139.43 | 2024-2025 | |
| Shire North American Group INC | $137.06 | 2019 | |
| Amicus Therapeutics, INC. | $111.42 | 2019-2023 | Galafold |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Kassis Akl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.